New BioMed Alliance statement on the EU pharmaceutical reform co-written by EHA

EHA and the BioMed Alliance

Collaboration lies at the heart of EHA’s policy and advocacy work. For years, as part of our focus on stakeholder involvement and alliances, we have been an active and leading member of the BioMed Alliance.

The BioMed Alliance serves as the collective voice for 35 European medical societies, and promotes excellence in biomedical research.

As part of the Alliance, we align and work together with other medical societies, benefit from increased visibility, and amplify our advocacy.

The EU pharmaceutical legislation

The revision of the EU pharmaceutical legislation is one of the most extensive reforms in over two decades.

It will have a considerable impact on patients, so it’s important to ‘get it right.’ You can read more about this on our dedicated page about the legislation’s revision.

As the Parliament, Council, and Commission negotiate a final version of both legislative texts, EHA and the BioMed Alliance call on EU policymakers to strike the right balance between:

• Improving patient access to medicines
• Addressing unmet medical needs
• Ensuring a sustainable, innovative healthcare system

The statement

The collective statement, co-written by EHA, stresses the need for a pharmaceutical framework that enhances the availability, affordability, and accessibility of medicines across the EU.

We urge policymakers to:

• Include quality of life in the definition of unmet medical need
• Retain strong measures to prevent medicine shortages
• Support drug repurposing and funding transparency
• Improve access to medicines for patients across the EU

You can read the full statement below.